ArticleFrontiers in immunology2026
Serum IL-32γ as a biomarker for remission assessment in systemic lupus erythematosus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the potential of serum interleukin (IL)-32γ levels as a biomarker for assessing lupus low disease activity state (LLDAS) and remission, the targets of a treat-to-target strategy, in patients with systemic lupus erythematosus (SLE). Methods: We analyzed sera from 40 patients with SLE. Serum IL-32γ levels were measured using an enzyme-linked immunosorbent assay, alongside conventional serologic markers (C3, C4, anti-double-stranded DNA antibody). Disease status was classified according to LLDAS, definition of remission in SLE (DORIS) remission, and glucocorticoid (GC)-free remission. Correlations with SLE disease activity index 2000 (SLEDAI-2K) were examined using Spearman's rank correlation coefficient, and receiver operating characteristic (ROC) curve analyses were performed to evaluate discriminative accuracy for disease state. Results: Serum IL-32γ levels correlated significantly with SLEDAI-2K (rho=0.401, p=0.010), as did the conventional serologic markers. In ROC analyses, IL-32γ was statistically significant in discriminating LLDAS (area under the curve [AUC]=0.728, p=0.014), similar to the other conventional serologic markers. However, for more stringent definitions, IL-32γ was the only serologic marker that retained statistical significance (DORIS remission: AUC = 0.785, p=0.014; and GC-free remission: AUC = 0.831, p=0.007). Conclusion: Serum IL-32γ is significantly associated with overall disease activity and shows promising discriminatory ability for disease states in SLE. Notably, it retains discriminative capacity in stringent remission definitions, underscoring its potential as a novel biomarker. These findings suggest that IL-32γ could complement existing tools in treat-to-target strategies, offering a simple serologic marker to guide therapy toward the ultimate goal of GC-free remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.